Ibrutinib and idelalisib synergistically target BCR-controlled adhesion in MCL and CLL: a rationale for combination therapy
Open Access
- 2 April 2015
- journal article
- Published by American Society of Hematology in Blood
- Vol. 125 (14), 2306-2309
- https://doi.org/10.1182/blood-2014-12-619163
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Faculty Opinions recommendation of Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.Published by H1 Connect ,2017
- Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid LeukemiaNew England Journal of Medicine, 2014
- Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor IbrutinibNew England Journal of Medicine, 2014
- A phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL)Blood, 2014
- Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemiaBlood, 2014
- Egress of CD19+CD5+ cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patientsBlood, 2013
- Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell LymphomaNew England Journal of Medicine, 2013
- Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic LeukemiaNew England Journal of Medicine, 2013
- P110α-mediated constitutive PI3K signaling limits the efficacy of p110δ-selective inhibition in mantle cell lymphoma, particularly with multiple relapseBlood, 2013
- The clinically active BTK inhibitor PCI-32765 targets B-cell receptor– and chemokine-controlled adhesion and migration in chronic lymphocytic leukemiaBlood, 2012